Table 2. Overview of results of patients with an osteoma-associated choroidal neovascular membrane (CNV) that were subjected to anti-VEGF treatment.
Patient | F/U (months) | VA initial | VA final | No of injections | CNV type | OCT CRT initial | OCT CRT final | CNV status |
---|---|---|---|---|---|---|---|---|
1 | 15 | CF | 6/24 | 10 | Min Classic | 297 | 291 | Partial regression |
2 | 12 | CF | 6/12 | 4 | Classic | 269 | 238 | Complete regression |
3 | 12 | 6/24 | 6/12 | 5 | Classic | 500 | 270 | Complete regression |
4 | 4 | 6/60 | 6/60 | 3 | Classic | NA | NA | Partial regression |
5 | 7 | 6/12 | 6/7.5 | 5 | Classic | 376 | 266 | Complete regression |
6 | 10 | 6/12 | 6/9 | 5 | Classic | 204 | 203 | Partial regression |
7 | 3 | 6/18 | 6/60 | 3 | Classic | 577 | 355 | Complete regression |
8 | 9 | 6/60 | CF | 7 | Occult | 342 | 206 | Complete regression |
Abbreviation: CRT, central retinal thickness.